171 related articles for article (PubMed ID: 201375)
1. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
Kleinman R; Dray S
Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
3. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
[TBL] [Abstract][Full Text] [Related]
4. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
Braun DP; Dray S
Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
[TBL] [Abstract][Full Text] [Related]
5. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
[TBL] [Abstract][Full Text] [Related]
6. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
9. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
11. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
12. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
13. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
Fenton MR; Havas HF
J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
[TBL] [Abstract][Full Text] [Related]
14. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
[TBL] [Abstract][Full Text] [Related]
15. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
[TBL] [Abstract][Full Text] [Related]
16. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
Platica M; Bojko C; Steiner G; Hollander VP
Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
[TBL] [Abstract][Full Text] [Related]
17. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
18. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
19. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
Takesue BY; Pyle JM; Mokyr MB
Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
[TBL] [Abstract][Full Text] [Related]
20. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
